Citable company snapshot
Abbott Laboratories's latest SEC-sourced 2026-03-31 period shows $11.16B in revenue and $1.10B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $11.16B | $11.46B | -2.6% |
| xbrl:GrossProfit | Dec 31, 2019 | $4.40B | $4.23B | +3.8% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $1.34B | $2.25B | -40.2% |
| xbrl:NetIncomeLossAvailableToCommonStockholdersBasic | Mar 31, 2026 | $1.10B | $1.75B | -37.3% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $1.31B | $3.31B | -60.3% |
| Free Cash Flow (computed) | Mar 31, 2026 | $916.00M | $2.63B | -65.1% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 29, 2026; accession 0001628280-26-028357.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
